NanoReady: A ready-made DC-selective delivery platform for personalized mRNA cancer vaccines with strong NHP immunogenicity
Journal of Controlled Release · 2026
DOI: 10.1016/j.jconrel.2026.115176 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Controlled Release, 2026. Verfasst von Sojin Lee und 9 weiteren Autor:innen. Beteiligte Einrichtung: R&D Center, Samyang Biopharm Corporation, Pangyo, South Korea. Hauptthemen laut MEDLINE: Cancer Vaccines, Dendritic Cells, RNA, Messenger, Nanoparticles. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
NanoReady is a next-generation mRNA delivery platform designed to overcome the limitations of conventional lipid-based systems, such as lipid nanoparticles (LNP) and Lipoplex (LPX), particularly for personalized cancer vaccines. It combines a novel cationic lipid with a biodegradable polymer, forming a stable nanoparticle that efficiently encapsulates mRNAs with a wide range of lengths. NanoReady nanoparticles can be pre-assembled without RNA as a ready-made formulation, and upon availability of patient-specific antigen-encoding mRNA, NanoReady rapidly incorporates the RNA to form uniform, administration-ready particles. NanoReady selectively delivers antigen mRNA to professional antigen-presenting cells, particularly dendritic cells in the spleen, where robust antigen-specific T-cell responses are elicited. When combined with mRNA, NanoReady forms multilamellar nanoparticles that exhibit high mRNA loading capacity and efficient endosomal release, leading to enhanced protein expression. As a result, it induces strong T-cell immune responses to the encoding antigen that overcomes immune tolerance when encoding self-antigens. In B16-F10 tumor mouse model, NanoReady mRNA vaccine encoding the self-antigen mTRP2 induced potent CD8 T-cell responses, resulting in significant tumor growth suppression and improved survival. Compared to DOTMA based LPX formulations, NanoReady achieved markedly higher antigen expression, stronger antigen-specific T cell immunogenicity, and superior anti-tumor efficacy. Importantly, a pilot non-human primate (NHP) study demonstrated antigen-specific T-cell immunogenicity following NanoReady-mRNA vaccination, supporting translational potential. Furthermore, repeated administration of NanoReady-mRNA vaccine showed no toxicity in various animal models confirming the platform's high biocompatibility and safety. These findings highlight NanoReady as a promising platform for personalized cancer vaccines, combining high mRNA delivery efficiency, robust immune response, and excellent safety.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- R&D Center, Samyang Biopharm Corporation, Pangyo, South Korea.
- CQC, Samyang Biopharm Corporation, Pangyo, South Korea.
- R&D Center, Samyang Biopharm Corporation, Pangyo, South Korea. Electronic address: helen.cho@samyang.com.
Zitieren
APA
Lee, S., Kim, S., Kim, S., Kyung, K., Kim, G., Nam, J., Lee, J., Jeong, S., Seo, G., & Cho, H. (2026). NanoReady: A ready-made DC-selective delivery platform for personalized mRNA cancer vaccines with strong NHP immunogenicity. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2026.115176
Vancouver
Lee S, Kim S, Kim S, Kyung K, Kim G, Nam J, et al. NanoReady: A ready-made DC-selective delivery platform for personalized mRNA cancer vaccines with strong NHP immunogenicity. Journal of Controlled Release. 2026. doi:10.1016/j.jconrel.2026.115176
BibTeX
@article{Lee2026,
author = {Lee, Sojin and Kim, Soyoung and Kim, Sooyeon and Kyung, Kyujin and Kim, Goeun and Nam, Jeongpyo and Lee, Jaeah and Jeong, Seungwei and Seo, Gunhee and Cho, Helen},
title = {NanoReady: A ready-made DC-selective delivery platform for personalized mRNA cancer vaccines with strong NHP immunogenicity},
journal = {Journal of Controlled Release},
year = {2026},
doi = {10.1016/j.jconrel.2026.115176}
}
EUVIMED